Search

Author/Creator Jaeger, U.

1. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019)

Authors:
Kalakonda, N.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.; Casasnovas, O.; Lavee, O.; Maerevoet, M.; Zijlstra, J.; Bakshi, S.; Bouabdallah, R.; Choquet, S.; Gurion, R.; Hill, B.; Jaeger, U.; Sancho, J.; Schuster, M.; Thieblemont, C.; De la Cruz, F.; Egyed, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
62
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. (12th June 2019)

Authors:
Bachanova, V.; Westin, J.; Tam, C.; Borchmann, P.; Jaeger, U.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Bishop, M.; Andreadis, C.; Foley, S.R.; Fleury, I.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Maziarz, R.; Van Besien, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
308
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS. (June 2017)

Authors:
Kipps, T.J.; Fraser, G.; Coutre, S.E.; Brown, J.R.; Barrientos, J.C.; Barr, P.M.; Byrd, J.C.; O'Brien, S.M.; Dilhuydy, M.; Hillmen, P.; Jaeger, U.; Moreno, C.; Cramer, P.; Stilgenbauer, S.; Chanan‐Khan, A.A.; Mahler, M.; Salman, M.; Cheng, M.; Londhe, A.; Ninomoto, J.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
109
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. (12th June 2019)

Authors:
Jaeger, U.; Tam, C.; Borchmann, P.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Andreadis, C.; Foley, S.R.; Fleury, I.; Westin, J.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Schuster, S.; Bachanova, V.; Maziarz, R.; Van Besien, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
505
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP. (June 2017)

Authors:
Montillo, M.; Byrd, J.C.; Hillmen, P.; O'Brien, S.; Barrientos, J.C.; Reddy, N.M.; Coutre, S.; Tam, C.S.; Mulligan, S.P.; Jaeger, U.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Thornton, P.; Moreno, C.; Pagel, J.M.; Burger, J.A.; Jones, J.; Dai, S.; Vezan, R.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
235
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. (17th June 2021)

Authors:
Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Provencio, M.; Jaeger, U.; Willenbacher, W.; Swanink, R.; Sacchi, M.; Shipp, M. A.; Engert, A.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY. (23rd June 2022)

Authors:
Dharnidharka, V.; Thirumalai, D.; Jaeger, U.; Zhao, W.; Dierickx, D.; Xun, P.; Minga, P.; Sawas, A.; Sadetsky, N.; Chauvet, P.; Sundaram, E.; Barlev, A.; Zimmerman, H.; Trappe, R. U.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
997
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION. (23rd June 2022)

Authors:
Jaeger, U.; Broome, C.; Go, R.; Patriarca, A.; Roeth, A.; Chang, Q.; Weedin, N.; Adams, P.; Cahir-McFarland, E.; Kroon, H.-A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1433
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗